Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106022 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
A Phase 1 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06106022 is a Phase 1 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT06106022, a Phase 1 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily \[QD\]) in children ≥ 6 to \< 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).
Interventions
- DRUG Vonoprazan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2024-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106022
The ClinicalTrials.gov registry entry for NCT06106022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phathom Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vonoprazan is the first listed.
NCT06106022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06106022 about?
NCT06106022 is a clinical study titled "A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease". The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily \[QD\]) in children ≥ 6 to \< 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).
What is the current status of trial NCT06106022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-11-01. Estimated completion is 2024-04-29.
What interventions are being tested in trial NCT06106022?
The interventions under investigation include: Vonoprazan (DRUG).
Who is sponsoring clinical trial NCT06106022?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.